The real downsides of Wegovy: what the evidence shows

What the STEP 1 trial also found: the side-effect picture

The headline from the STEP 1 trial is the 15% average weight loss. Less discussed is what participants experienced along the way. Gastrointestinal effects were the most common: nausea, vomiting, diarrhoea, constipation and indigestion affected a substantial proportion of people taking the 2.4mg maintenance dose, and these reactions drove most of the discontinuations in the trial. For many participants the symptoms were mild and settled within a couple of weeks of each dose step. For others they were persistent enough to stop treatment altogether.

The NHS medicines page for semaglutide lists the common effects clearly: nausea tends to be the most reported, followed by diarrhoea and constipation (sometimes alternating) along with burping, reflux and fatigue. Headaches and dizziness appear less often but are documented. Injection-site reactions are generally minor. The pattern is familiar to prescribers: symptoms are most noticeable after starting and after each dose increase, then typically ease. That said, "typically" is not the same as "always", and it is honest to say that a minority of people find the GI effects a reason to stop.

There is also a practical downside that does not appear in trial papers: the weekly injection itself. Some people adapt quickly; others find the self-injection aspect harder than they expected. It is a question worth sitting with before you start, not after.

The pancreatitis warning and other risks that need more than a footnote

Some downsides of semaglutide are infrequent but serious enough to treat as genuine red flags rather than small-print qualifications. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 receptor agonists, including Wegovy, specifically highlighting acute pancreatitis. The update advised that anyone experiencing severe or persistent abdominal pain (particularly pain that spreads to the back, with or without vomiting) should seek urgent medical attention and stop the medicine until assessed. The risk is considered uncommon relative to the number of people taking these treatments, but uncommon is not zero.

Gallbladder problems, including gallstones, have also been reported. Rapid weight loss in general can affect gallbladder function, and GLP-1 medicines appear to carry an independent contribution. People with a history of gallbladder disease should discuss this specifically with their prescriber before starting.

Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. Those with a personal or close family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, should not take it. A prescriber works through all of this during a clinical assessment, it is not a checklist you complete alone. If you are thinking about what Wegovy involves in more depth, that page covers the full picture of the treatment.

The limitations that trial data alone do not resolve

Perhaps the most significant practical downside is what happens when treatment ends. Semaglutide works while you take it. Clinical evidence consistently shows that people who stop regain a substantial proportion of lost weight within a year or two unless the lifestyle changes made during treatment are maintained. Weight regain after stopping GLP-1 medicines is not a personal failing (it reflects how appetite regulation works biologically) but it does mean Wegovy is rarely a short course in the way a course of antibiotics is. That changes the cost calculation considerably, and it is worth reading about the broader semaglutide evidence base if you want to understand long-term use data.

There is also the question of what Wegovy will not do. It is not effective without a reduced-calorie diet and increased physical activity running alongside it. The trial populations all received lifestyle support. Using the medicine without those foundations in place produces smaller results, and sometimes none. If you are curious about what the medicine actually does in the body, how Wegovy affects fat metabolism is answered in more detail elsewhere.

For anyone currently weighing up options, the wider documented benefits of semaglutide beyond weight loss are worth knowing too (including cardiovascular evidence) so that the decision is genuinely balanced rather than just a list of risks. If you want a thorough look at what the downsides of Wegovy include across all the main categories, that page brings together the full picture in one place. Understanding the downsides to Wegovy is important; so is understanding what goes in the other column.

Who should be especially cautious, and what the consultation is for

If you have read this far and feel a little uncertain, that is a reasonable response to an honest account. Many people arrive at this question after weeks of reading conflicting claims online, and the scepticism is usually warranted. A prescription-only medicine with a meaningful side-effect profile and a long-term commitment attached to it deserves careful thought.

The clinical consultation exists precisely for this. A prescriber reviews your medical history, current medicines (oral contraceptives, for instance, may be affected by Wegovy's effect on gastric emptying and may need a backup method during dose increases), and whether your BMI and health profile sit within the licensed criteria. They are also the right person to talk through the semaglutide downsides that apply specifically to you, not the average across a trial population, but your picture. Some people also ask whether semaglutide shows up in routine bloodwork, and that is a good example of the kind of practical question worth raising at the consultation rather than worrying about afterwards. Our clinical team at nume reviews every consultation personally; if Wegovy is not the right fit, that conversation happens at assessment, not after a prescription has been issued.

For a broader look at what weight-loss treatment with a GLP-1 medicine involves from the start, the weight-loss treatment overview sets out how the process works. If you have specific questions before committing to anything, the FAQs cover the most common ones. When you are ready to speak to a prescriber, starting a free consultation is the next step.